BiotechTube

Solriamfetol 150 MG + Placebo

Phase 3Recruiting
1 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Conditions

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Trial Timeline

Feb 23, 2026 → Dec 1, 2028

NCT ID
NCT07484217

About Solriamfetol 150 MG + Placebo

Solriamfetol 150 MG + Placebo is a phase 3 stage product being developed by Axsome Therapeutics for Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07484217. Target conditions include Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms were approved

Approved (20) Terminated (0) Active (0)
✅Mirtazapine TabletsSun PharmaceuticalApproved
✅DuloxetineEli LillyApproved
✅duloxetineEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07484217Phase 3Recruiting

Competing Products

20 competing products in Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
26
LY2216684Eli LillyPhase 1
29
LY2216684Eli LillyPhase 1
29
DuloxetineEli LillyPhase 3
40
LY2216684 + DigoxinEli LillyPhase 1
29
Duloxetine + ParoxetineEli LillyPhase 3
40
Duloxetine + placeboEli LillyPhase 3
40
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
35
FK949EAstellas PharmaPhase 1
29
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
35
FK949EAstellas PharmaPhase 1
29
FK949EAstellas PharmaPhase 1
29
FK949EAstellas PharmaPhase 1
29
Mirtazapine TabletsSun PharmaceuticalApproved
43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Pramipexole ER + EscitalopramCiplaPhase 2
42
LY2216684 + SertralineEli LillyPhase 1
29
LY2216684 + Placebo + LorazepamEli LillyPhase 1
29
LY2216684 + SSRIEli LillyPhase 3
40